Cognitive Behavior vs Bright Light Therapy for Insomnia in Women Undergoing Chemotherapy for Breast Cancer: A - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Comparative Effectiveness of Cognitive Behavioral Therapy and Bright Light Treatment for Insomnia in Women with Breast Cancer Undergoing Chemotherapy

  • By

  • Trang Thuy Do

  • Jordan Maccora

  • Rebecca Wallace

  • Veronica Aedo-Lopez

  • Marliese Alexander

  • Sonia Ancoli-Israel

  • Bei Bei

  • Robert Blum

  • Frances Boyle

  • Daphne Day

  • Justine Diggens

  • Prudence A. Francis

  • Maria Ftanou

  • Sheila N. Garland

  • Alysia Kepert

  • Duncan Mortimer

  • Andrew J. K. Phillips

  • Sharad Sharma

  • Lesley Stafford

  • Michelle White

  • Joshua F. Wiley

  • August 27, 2026

Share

Original Source(s)

Cognitive Behavior vs Bright Light Therapy for Insomnia in Women Undergoing Chemotherapy for Breast Cancer: A

  • by Trang Thuy Do, Jordan Maccora, Rebecca Wallace, Veronica Aedo-Lopez, Marliese Alexander, Sonia Ancoli-Israel, Bei Bei, Robert Blum, Frances Boyle, Daphne Day, Justine Diggens, Prudence A. Francis, Maria Ftanou, Sheila N. Garland, Alysia Kepert, Duncan Mortimer, Andrew J. K. Phillips, Sharad Sharma, Lesley Stafford, Michelle White, Joshua F. Wiley

  • August 27, 2026

Related Content

Error in the Byline

  • August 27, 2026

Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas

FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer Following Landmark Clinical Trial Led by Dana-Farber

he U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

  • by

  • August 26, 2026

  • 5 min